| Consumer Finance Industry | Financials Sector | Jeffrey Volpe CEO | OTC GREY Exchange | 09689P103 CUSIP |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Based in Irvine, California, BodyScan Corp. specializes in advanced medical imaging services. Its primary focus is on utilizing cutting-edge GE-Imatron Electron Beam Tomography (EBT) technology. This technology is instrumental in diagnosing a wide range of health conditions, including coronary artery disease (CAD), lung diseases, and the detection of tumors and stones within the body. The company's expertise in deploying this sophisticated imaging method offers a significant advantage in early and accurate disease detection, which is critical for effective treatment and management. BodyScan Corp. aims to provide high-quality medical imaging services that contribute to improved patient outcomes.
This premium imaging service focuses on the early detection of CAD, a leading cause of heart disease. By utilizing EBT, BodyScan Corp. can offer non-invasive, detailed images of the coronary arteries, enabling the early identification and management of potential heart health risks.
BodyScan Corp. leverages the EBT technology to detect various lung diseases at an early stage. This service is crucial for patients at risk of lung conditions, providing them with accurate diagnoses and facilitating timely medical intervention.
The use of EBT scanning by BodyScan Corp. extends to the identification and assessment of tumors. This technology allows for high-resolution images that help in determining the presence, size, and location of tumors, which is vital for planning appropriate treatment strategies.
BodyScan Corp.'s services also encompass the detection of stones in the body, such as kidney stones or gallstones. Through EBT scans, the company can identify and evaluate stones, aiding in the diagnosis and guiding the choice of treatment procedure for patients.